Clinical Trial Search

Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001

Primary: Overall Palatability Visual Analogue Scale (VAS) Score at 0 Minute (Right After the Spit-out of the Investigational Medicinal Product [IMP]) — 49.0; 39.3; 67.5; 51.4…

Primary: Vacc-4x Effect on Viral Load Set-point — 38455.0; 40088.8; 45253.9; 47336.8 Copies/mL

Primary: Quality of Postoperative Recovery Assessed by QoR-40 Questionnaire 24 Hours After Surgery — 187.8; 189.6; 186.8 units on a scale

Primary: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 — 31.4; 18.0 percentage of participants — p=<0.001

Primary: Monocular Uncorrected Distance Decimal Visual Acuity — 3; 3; 1; 0 participants

Primary: Cmax of AZD9291 After Single Dosing — 103.8; 195.9 nmol/L

Primary: Change From Baseline in Schiff Sensitivity Score of Experimental Oral Rinses 1 and 2 Against a Placebo Oral Rinse at Week 8 — 2.54; 2.56; 2.55; -0.86 score on a scale…

Primary: Maximum Change From Baseline Concentration (Cmax) of Glucagon — 6290.33; 3463.55; 3958.58; 4743.00 picograms per millilitre (pg/mL)

Primary: Jebsen Taylor Hand Function Test — 68; 80 seconds

Primary: Number of Adverse Events — 5; 5 adverse events

Primary: Mean Change From Baseline in Total Physical Activity Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH) Score — 870.0 units on a scale

Primary: Inferior Corneal Fluorescein Staining Score in Pre-Controlled Adverse Environment at Day 84 — 2.03; 1.92; 1.83; 2.05 units on a scale — p=0.9381

Primary: Mean Monocular Uncorrected Distance Visual Acuity (UCDVA) at Fixed Distance at Visit 5 — 0.126; 0.125 logMAR

Primary: Number of Participants With Dose Limiting Toxicities During Cycle 1 — 0; 1; 1; 2 participants with DLT